Classical nephroprotection : Renin angiotensin aldosterone system inhibitors
Copyright © 2023 Sociedad Española de Médicos de Atención Primaria (SEMERGEN). Publicado por Elsevier España, S.L.U. All rights reserved..
The role of the renin angiotensin aldosterone system (RAAS) in the pathophysiology of hypertension, cardiovascular disease and kidney disease has been known for years. RAAS inhibitors have been the mainstay of chronic kidney disease (CKD) treatment. Studies have shown that therapy with angiotensin-converting enzyme inhibitors (ACE inhibitors) or angiotensinII receptor blockers (ARBs) reduce the excretion of albuminuria and slow the progression of kidney disease in patients with and without diabetes. In clinical practice, RAAS inhibitors are recommended as the antihypertensive of choice in patients with CKD and albuminuria with or without diabetes. In addition, they have demonstrated cardiovascular benefits beyond blood pressure control. The use of RAAS inhibitors in non-proteinuric nephropathy and advanced CKD is not without controversy. Double blockade of the RAAS is contraindicated. On the other hand, it is essential to know how to titrate doses and avoid side effects, mainly hyperkalaemia.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:49 Suppl 1 |
|---|---|
| Enthalten in: |
Semergen - 49 Suppl 1(2023) vom: 24. Juni, Seite 102018 |
| Sprache: |
Spanisch |
|---|
| Weiterer Titel: |
Nefroprotección clásica: inhibidores del sistema renina angiotensina aldosterona |
|---|
| Beteiligte Personen: |
Egocheaga, M I [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 26.06.2023 Date Revised 26.06.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.semerg.2023.102018 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358566630 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358566630 | ||
| 003 | DE-627 | ||
| 005 | 20231226075025.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||spa c | ||
| 024 | 7 | |a 10.1016/j.semerg.2023.102018 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1195.xml |
| 035 | |a (DE-627)NLM358566630 | ||
| 035 | |a (NLM)37355297 | ||
| 035 | |a (PII)S1138-3593(23)00097-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a spa | ||
| 100 | 1 | |a Egocheaga, M I |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Classical nephroprotection |b Renin angiotensin aldosterone system inhibitors |
| 246 | 3 | 3 | |a Nefroprotección clásica: inhibidores del sistema renina angiotensina aldosterona |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.06.2023 | ||
| 500 | |a Date Revised 26.06.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Sociedad Española de Médicos de Atención Primaria (SEMERGEN). Publicado por Elsevier España, S.L.U. All rights reserved. | ||
| 520 | |a The role of the renin angiotensin aldosterone system (RAAS) in the pathophysiology of hypertension, cardiovascular disease and kidney disease has been known for years. RAAS inhibitors have been the mainstay of chronic kidney disease (CKD) treatment. Studies have shown that therapy with angiotensin-converting enzyme inhibitors (ACE inhibitors) or angiotensinII receptor blockers (ARBs) reduce the excretion of albuminuria and slow the progression of kidney disease in patients with and without diabetes. In clinical practice, RAAS inhibitors are recommended as the antihypertensive of choice in patients with CKD and albuminuria with or without diabetes. In addition, they have demonstrated cardiovascular benefits beyond blood pressure control. The use of RAAS inhibitors in non-proteinuric nephropathy and advanced CKD is not without controversy. Double blockade of the RAAS is contraindicated. On the other hand, it is essential to know how to titrate doses and avoid side effects, mainly hyperkalaemia | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Chronic kidney disease | |
| 650 | 4 | |a Enfermedad renal crónica | |
| 650 | 4 | |a Nefropatía | |
| 650 | 4 | |a Nephropathy | |
| 650 | 4 | |a Renin angiotensin aldosterone system | |
| 650 | 4 | |a Sistema renina angiotensina aldosterona | |
| 650 | 7 | |a Angiotensin-Converting Enzyme Inhibitors |2 NLM | |
| 650 | 7 | |a Angiotensin Receptor Antagonists |2 NLM | |
| 700 | 1 | |a Drak, Y |e verfasserin |4 aut | |
| 700 | 1 | |a Otero, V |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Semergen |d 1998 |g 49 Suppl 1(2023) vom: 24. Juni, Seite 102018 |w (DE-627)NLM095511652 |x 1578-8865 |7 nnns |
| 773 | 1 | 8 | |g volume:49 Suppl 1 |g year:2023 |g day:24 |g month:06 |g pages:102018 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.semerg.2023.102018 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 49 Suppl 1 |j 2023 |b 24 |c 06 |h 102018 | ||